Detalles de la búsqueda
1.
Impact of JIA on parents' work absences.
Rheumatology (Oxford)
; 54(7): 1177-85, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25504895
2.
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
Ann Rheum Dis
; 72(7): 1156-62, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22915617
3.
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
BMJ Open
; 5(6): e006560, 2015 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26059521
4.
Parent-reported outcomes for treatment of acute otitis media with cefdinir or amoxicillin/clavulanate oral suspensions.
Paediatr Drugs
; 6(6): 387-93, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15612839
5.
Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis.
J Occup Environ Med
; 55(3): 240-4, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23471034
6.
Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.
Arthritis Care Res (Hoboken)
; 65(8): 1299-306, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23436774
7.
Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
J Rheumatol
; 39(1): 63-72, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22045836
8.
Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
J Manag Care Pharm
; 17(4): 313-20, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21534642
9.
Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
Arthritis Care Res (Hoboken)
; 62(2): 226-34, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20191522
10.
Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Clin Infect Dis
; 39(1): 144-5; author reply 145-6, 2004 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15206068
11.
Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Curr Med Res Opin
; 20(12): 1895-6; author reply 1896-7, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15701207
12.
Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
J Rheumatol
; 36(1): 16-26, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19012363
13.
Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.
J Rheumatol
; 34(12): 2343-50, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17918788
14.
Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections.
COPD
; 2(2): 217-23, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17136948
Resultados
1 -
14
de 14
1
Próxima >
>>